1. Home
  2. FOSL vs ADVM Comparison

FOSL vs ADVM Comparison

Compare FOSL & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FOSL
  • ADVM
  • Stock Information
  • Founded
  • FOSL 1984
  • ADVM 2006
  • Country
  • FOSL United States
  • ADVM United States
  • Employees
  • FOSL N/A
  • ADVM N/A
  • Industry
  • FOSL Consumer Specialties
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FOSL Consumer Discretionary
  • ADVM Health Care
  • Exchange
  • FOSL Nasdaq
  • ADVM Nasdaq
  • Market Cap
  • FOSL 100.0M
  • ADVM 119.6M
  • IPO Year
  • FOSL 1993
  • ADVM 2014
  • Fundamental
  • Price
  • FOSL $1.54
  • ADVM $3.94
  • Analyst Decision
  • FOSL
  • ADVM Strong Buy
  • Analyst Count
  • FOSL 0
  • ADVM 6
  • Target Price
  • FOSL N/A
  • ADVM $27.83
  • AVG Volume (30 Days)
  • FOSL 228.1K
  • ADVM 149.4K
  • Earning Date
  • FOSL 03-12-2025
  • ADVM 03-17-2025
  • Dividend Yield
  • FOSL N/A
  • ADVM N/A
  • EPS Growth
  • FOSL N/A
  • ADVM N/A
  • EPS
  • FOSL N/A
  • ADVM N/A
  • Revenue
  • FOSL $1,223,954,000.00
  • ADVM $1,000,000.00
  • Revenue This Year
  • FOSL N/A
  • ADVM N/A
  • Revenue Next Year
  • FOSL N/A
  • ADVM $1,342.84
  • P/E Ratio
  • FOSL N/A
  • ADVM N/A
  • Revenue Growth
  • FOSL N/A
  • ADVM N/A
  • 52 Week Low
  • FOSL $0.75
  • ADVM $3.85
  • 52 Week High
  • FOSL $2.61
  • ADVM $22.30
  • Technical
  • Relative Strength Index (RSI)
  • FOSL 39.03
  • ADVM 38.74
  • Support Level
  • FOSL $1.60
  • ADVM $3.85
  • Resistance Level
  • FOSL $1.80
  • ADVM $4.63
  • Average True Range (ATR)
  • FOSL 0.11
  • ADVM 0.30
  • MACD
  • FOSL -0.01
  • ADVM -0.01
  • Stochastic Oscillator
  • FOSL 5.71
  • ADVM 8.76

About FOSL Fossil Group Inc.

Fossil Group Inc is a design, innovation and distribution company in consumer fashion accessories. The products include traditional watches, smartwatches, jewelry, handbags, small leather goods, belts and sunglasses. The reportable segments are comprised of 1) Americas segment includes sales in Canada, Latin America and the United States. 2) Europe segment includes sales in European countries, the Middle East and Africa. 3) Asia segment includes sales in Australia, China, India, Indonesia, Japan, Malaysia, New Zealand, Singapore, South Korea and Thailand. Each reportable operating segment includes sales to wholesale and distributor customers, and sales through Company-owned retail stores and e-commerce activities based on the location of the selling entity.

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Share on Social Networks: